NT PHARMA-NEW: TERMINATION OF THE VERY SUBSTANTIAL ACQUISITION IN RELATION TO THE LICENSING OF COMMERCIALISATION RIGHT AND CHANGE IN USE OF PROCEEDS FROM THE PLACING
NT PHARMA: (1) MAJOR TRANSACTION IN RELATION TO THE DISPOSAL OF THE ENTIRE ISSUED SHARE CAPITAL OF THE TARGET COMPANY; AND(2) NOTICE OF EGM
NT PHARMA: FURTHER DELAY IN DESPATCH OF CIRCULAR
NT PHARMA: DELAY IN DESPATCH OF CIRCULAR
NT PHARMA: MAJOR TRANSACTION IN RELATION TO THE DISPOSAL OF THE ENTIRE ISSUED SHARE CAPITAL OF THE TARGET COMPANY
NT PHARMA: (1) VERY SUBSTANTIAL DISPOSAL IN RELATION TO THE PROPOSED DISPOSAL OF THE ENTIRE ISSUED SHARE CAPITAL OF NT PHARMA INTERNATIONAL; (2) VERY SUBSTANTIAL ACQUISITIONIN RELATION TO THE PROPOSED ACQUISITION OF 40% EQUITY INTERESTS IN KANGCHEN; AND
NT PHARMA: DELAY IN DESPATCH OF CIRCULAR IN RELATION TO THE VERY SUBSTANTIAL DISPOSAL AND THE VERY SUBSTANTIAL ACQUISITION
No Data